CagriSema Has Been Submitted to the FDA: What Happens Next?
CagriSema has officially reached the milestone I have been waiting for: Novo Nordisk has submitted a New Drug Application to the FDA for chronic weight management.
For anyone who has been following the cagrilintide story from the early amylin research through Phase 2 and then the REDEFINE Phase 3 program, this is a big transition. The question is no longer simply whether the combination can produce meaningful weight loss in trials. The full package is now in the hands of FDA reviewers.
What exactly was submitted?
CagriSema combines once-weekly cagrilintide 2.4 mg, a long-acting amylin analogue, with semaglutide 2.4 mg, a GLP-1 receptor agonist.
The application is supported by the REDEFINE program, including REDEFINE 1 in adults without diabetes and REDEFINE 2 in adults with type 2 diabetes.
In REDEFINE 1, average weight reduction was 20.4% at 68 weeks in the treatment-policy analysis versus 3.0% with placebo. In the analysis estimating the effect if participants remained on treatment, average weight reduction was 22.7%.
What happens after an FDA submission?
An FDA submission does not mean a decision happens immediately. The agency first determines whether the application is sufficiently complete to be filed for substantive review. FDA guidance describes a 60-day filing window for a New Drug Application.
Once an application is filed, reviewers examine far more than a headline efficacy number. The package includes clinical data, safety analyses, manufacturing information, proposed labeling, and other information needed to decide how the medication should be used if approved.
Why I think this milestone matters
The most interesting part of CagriSema has always been the mechanism. Semaglutide and cagrilintide reach two different hormone systems—GLP-1 and amylin. If this combination ultimately becomes available, it would bring an amylin-based strategy into a much more prominent place in obesity treatment.
Novo Nordisk says FDA review is expected during 2026. I will be watching the process closely, because this is one of the clearest examples yet of where the post-semaglutide era of weight management may be headed.
Comments